{
  "slug": "pathware",
  "name": "Pathware",
  "description": "Pathware provides real-time biopsy quality assessment with its Bioptic™ system to eliminate diagnostic delays and inadequate biopsies, reducing patient stress, repeat procedures, and healthcare costs for hospitals and insurance.",
  "url": "https://optimly.ai/brand/pathware",
  "websiteUrl": "https://pathware.com/",
  "logoUrl": "https://logo.clearbit.com/pathware.com",
  "baiScore": 47.5,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "Clinical Diagnostic Systems",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-09-25T21:54:13.185Z",
  "verifiedVitals": {
    "website": "https://pathware.com",
    "category": "Digital Pathology",
    "what_it_does": "Pathware provides real-time biopsy quality assessment using its Bioptic™ platform, which integrates computational microscopy and AI to analyze tissue samples at the point of care. This aims to reduce inadequate biopsies, improve diagnostic accuracy, and eliminate the need for repeated procedures by verifying sample quality and transmitting digital images for remote interpretation.",
    "primary_audience": "Patients, Pathologists, Hospitals, and Insurance companies.",
    "core_product": "Bioptic™, a cloud-based imaging and sample management platform for real-time biopsy quality assessment.",
    "pricing_model": {
      "kind": "usage_based",
      "detail": "Pathware generates revenue by sharing new reimbursement revenue with client institutions, with monthly billing based on hardware utilization. The remote viewing software is free."
    },
    "parent_ownership": null,
    "named_competitors": [
      "Prenuvo",
      "Samplify",
      "IdentifySensors"
    ]
  },
  "intentTags": {
    "problemIntents": [
      "Inadequate biopsies for diagnosis",
      "Delays in biopsy diagnosis",
      "Patient readmissions and re-biopsies",
      "Intermediary patient stress due to diagnostic waits",
      "Low billing potential for pathologists during on-site evaluations",
      "High aggregate costs of repeat biopsy procedures and unnecessary surgeries",
      "Unnecessary surgeries (e.g., thyroidectomies) following indeterminate biopsies",
      "Financial losses for insurance due to unwarranted medical procedures"
    ],
    "solutionIntents": [
      "Achieve real-time biopsy quality assessment",
      "Ensure biopsy adequacy for diagnosis",
      "Reduce the need for repeat biopsy procedures",
      "Decrease patient stress related to diagnostic delays",
      "Optimize pathologist efficiency during on-site evaluations",
      "Lower healthcare costs associated with biopsies and surgeries",
      "Prevent unnecessary surgeries through accurate, timely diagnosis"
    ],
    "evaluationIntents": [
      "Biopsy adequacy rates",
      "Diagnostic turnaround time for biopsies",
      "Cost savings in biopsy procedures and related surgeries",
      "Efficiency of on-site pathology assessment",
      "Reduction in patient re-biopsies and readmissions",
      "Accuracy of real-time diagnostic tools",
      "Impact on insurance claims for medical procedures"
    ]
  },
  "businessProfileClaims": [],
  "timestamp": 1790400164194
}